9 recruiting, 2 active not recruiting, 1 completed, 1 not yet recruiting. 13 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Recruiting 9, Active not recruiting 2, Completed 1, Not yet recruiting 1 |
Follow T-DXd: new trials by email Literature Review of T-DXd trials Research Report on T-DXd
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab Deruxtecan Dexamethasone, antiemetic premedication, T-DXd - Breast Cancer, Interstitial Lung Disease (ILD) | Phase 3 | Not yet recruiting | Mario Negri Institute for Pharmacological Research | 244 | 2026-12-20 | 2026-10-19 |
| T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd Trastuzumab deruxtecan, Trastuzumab, Pertuzumab - Advanced Breast Cancer, Metastatic Breast Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 200 | 2026-11-04 | 2026-11-17 |
| Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer Trastuzumab Deruxtecan, pembrolizumab, Pemetrexed - Non-small Cell Lung Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 686 | 2025-10-24 | 2026-11-18 |
| A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting Trastuzumab Deruxtecan, Chemotherapy - Endometrial Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 710 | 2025-09-30 | 2026-10-27 |
| A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) Patritumab deruxtecan, Paclitaxel, Nab-paclitaxel - Breast Neoplasms | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1000 | 2025-07-21 | 2026-11-03 |
| Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) Trastuzumab Deruxtecan, Bevacizumab - Ovarian Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 582 | 2025-03-19 | 2026-10-28 |
| Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer Trastuzumab Deruxtecan, pembrolizumab, Trastuzumab - Gastric Cancer, Gastroesophageal Junction Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 726 | 2025-02-27 | 2026-08-10 |
| A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) T-DXd - Advanced Cancer, Metastatic Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 75 | 2024-01-05 | 2026-10-26 |
| Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer Trastuzumab Deruxtecan - Breast Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 250 | 2023-12-30 | 2026-06-12 |
| Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab - Breast Neoplasms, Breast Cancer | Phase 3 | Active not recruiting | AstraZeneca | 927 | 2021-10-25 | 2026-08-11 |
| Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) Trastuzumab deruxtecan, Ramucirumab, Paclitaxel - Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Active not recruiting | Daiichi Sankyo | 490 | 2021-05-21 | 2026-05-27 |
| DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] Trastuzumab deruxtecan, Capecitabine, Lapatinib - Breast Cancer | Phase 3 | Completed | Daiichi Sankyo | 608 | 2018-08-01 | 2026-02-27 |
Breast Neoplasms (6) · Stomach Neoplasms (2) · Adenocarcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Endometrial Neoplasms (1) · Lung Diseases, Interstitial (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1)
Daiichi Sankyo (9) · AstraZeneca (1) · Mario Negri Institute for Pharmacological Research (1) · Merck Sharp & Dohme LLC (1) · SWOG Cancer Research Network (1)
United States (11) · Italy (10) · Spain (10) · Brazil (9) · China (9) · Japan (9) · South Korea (9) · France (8) · Germany (8) · Taiwan (8) · Poland (7) · Australia (6) · Belgium (6) · Israel (6) · Turkey (Türkiye) (6)
Mariya Rozenblit (1)
PMID 37086745, PMID 38697155, PMID 40341124, PMID 40454632, PMID 41342740, PMID 42682104
2023 (3), 2025 (2), 2018 (1), U10CA180888 (1)